Getinge AB (publ) (GETI_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to today's call. This is Patricius Pördös with me. I have our CFO, Agnetha Palmeer. In today's conference, we'll first look into our performance in the second quarter of 2025 and then also talk a bit about the current market situations and our expectations for 2025. So we can move directly over to page number two, please. I wanted to start with a quick repetition of our overall ambitions and how to get there. As you already know, our financial target for 2024 to 2028 is to have at least 12% adjusted EPS growth on average. We believe we have a strategy that is well crafted to get us to this goal. It's really based on our market positions in leading categories and the strength that we have in the different key geographies globally as well. And part of this is, of course, increasing the share of sales from recurring revenue. It's accelerating the share of sales from higher margin products like our Paragonics offering, our ECLS portfolio, the consumables in infection control and our beta bags in sterile transfer. And it's also a strategy that involves, of course, solid and effective quality processes going forward. These improvements should, of course, be achieved through responsible leverage as well and an attractive long term return on invested capital. We can clearly see that we are delivering according to the plan on these KPIs. We're trending in the right direction on all of them. Sales from recurring revenue is now at 65% and it was even higher now at the beginning of the first half of this year. But I would like to remind you that we are more weighted towards capital, especially in the fourth quarter of the year. High margin products make up about two thirds of sales. For quality, the number of field actions in relation to sales has decreased sign...